GlassScriptPhysician profile
Murphy S Martin
NPI 1801971908
$2,527.50
in general payments reported to CMS, 2019-2025
21 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $123 · 2021: $378 · 2022: $659 · 2023: $541 · 2024: $460 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227 · Education: $20.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.18 |
| Education | $20.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $495.63 | 2021-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $485.49 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $345.54 | 2019-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $315.52 | 2019-2025 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $208.62 | 2021-2024 | |
| Smith+Nephew, INC. | $117.37 | 2022 | |
| Depuy Synthes Sales INC. | $110.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $49.78 | 2019-2025 | |
| Horizon Therapeutics Plc | $48.47 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $46.07 | 2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $39.28 | 2022 | |
| Travere Therapeutics, INC. | $37.96 | 2023-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.77 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $34.33 | 2023-2024 | Ibsrela |
| Shire North American Group INC | $28.51 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $28.30 | 2024 | |
| Vifor Pharma, INC. | $24.20 | 2022 | |
| Amgen INC. | $21.18 | 2019 | |
| Genzyme Corporation | $20.04 | 2020 | |
| Baxter Healthcare | $19.98 | 2024 | Renal - Pd |
| Lilly USA, LLC | $14.66 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murphy Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.